GSK Swaps Cancer For Vaccines As It Sheds Legacy Products, Not R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
Complex transaction with Novartis leaves the British drug maker with a better balanced portfolio centered on vaccines, consumer health, respiratory and HIV medicines.
You may also be interested in...
Walmsley Takes On Oncology: Can GSK Become A Power Player?
GlaxoSmithKline's new CEO is assembling a "dream team" to rebuild the big pharma's R&D pipeline with an emphasis on building in oncology. Walmsley outlined her strategy at J.P. Morgan, while Oncology Therapy Area Head Axel Hoos provided more details in an interview.
Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.
Roche R&D Spending Surge Reflects In-House Innovation, M&A Prices
A surprise surge in Roche's R&D spending this year reflects high quality in-house innovation opportunities as well as high prices for external M&A targets, management said.